Skip to main content
. 2022 Mar 14;11(3):551. doi: 10.3390/antiox11030551

Table 2.

Demographic and clinical characteristics of the participants.

Variable Healthy
(n = 80)
MCI-AD
(n = 106)
MD-AD
(n = 70)
AD-AD
(n = 11)
Non-AD
(n = 20)
p Value
(Kruskal-Wallis Test)
Demographic characteristics
Age (years, median (IQR)) 63 (61–68) 70 (67–74) 71 (67–74) 66 (70–73) 65 (59–71) <0.01
Gender (female (%)) 44 (55%) 61 (57.5%) 46 (65.7%) 7 (63.6%) 11 (55%) 0.70
Level of education
n (%)
Basic
Secondary
University
22 (27.5%)
21 (26.3%)
37 (46.3%)
59 (55.7%)
23 (21.7%)
24 (22.6%)
41 (58.6%)
16 (22.9%)
13 (18.6%)
9 (81.8%)
1 (9.1%)
1 (9.1%)
14 (70%)
3 (15%)
3 (15%)
<0.01
Clinical characteristics
β-Amyloid-42 (pg·mL−1, median (IQR)) 1201 (942.75–1439.75) 597 (471.05–709.07) 574 (444.75–648.50) 636 (601.76–708.88) 982 (858–1647) <0.01
t-tau (pg·mL−1, median (IQR)) 224 (173.25–304) 583 (432.50–773.50) 621 (448.50–945.50) 699 (473–936) 289 (205–376) <0.01
p-tau (pg·mL−1, median (IQR)) 36 (28–47.25) 90 (70.50–109.50) 88.50 (73–144) 95 (73–122) 40 (32–61) <0.01
ADCS-ADL-MCI (median (IQR)) 47 (43–50.75) 41 (31–46) 36 (24–42) 29.50 (3–34.50) 29 (22.50–40.75) <0.01
CDR (median (IQR)) 0 (0–0) 0.5 (0.5–0.5) 1 (0.5–1) 2 (2–3) 1 (0.5–1) <0.01
FAQ (median (IQR)) 0 (0–2) 4 (1–7) 13 (10–17.25) 21 (14–25) 11.50 (8–21) <0.01
MMSE (median (IQR)) 29 (28–30) 25 (22–27.25) 20 (17.75–24) 14 (12–19) 23 (18–25) <0.01
RBANS.DM (median (IQR)) 100 (95–106) 52 (40–75) 40 (40–49) 40 (40–44) 58 (45–78) <0.01

t-tau: total tau; p-tau: phosphorylated tau; ADCS-ADL-MACI: AD Co-operative Study ADL Scale for Mild Cognitive Impairment; CDR: Clinical Dementia Rating; FAQ: Functionality Assessment Questionnaire; MMSE: Mini-Mental State Examination; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status (DM: delayed memory; A: attention; L: learning; VC: visuospatial/constructional; IM: immediate memory).